Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors

Journal of Nuclear Medicine

Volumn 40, Issue 4, 1999, Pages 631-638

  Akabani, Gamal ^a   Reist, Craig J ^a   Cokgor, Ilkcan ^a   Friedman, Allan H ^a   Friedman, Henry S ^a   Coleman, R Edward ^a   Zhao, Xiao Guang ^a   Bigner, Darell D ^a   Zalutsky, Michael R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Brain tumors; Dosimetry; Radioimmunotherapy

Indexed keywords

IODINE 131; MONOCLONAL ANTIBODY; RADIOACTIVE IODINE; TENASCIN;

ARTICLE; BRAIN TUMOR; CLINICAL ARTICLE; DOSIMETRY; GLIOBLASTOMA; HUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR RECURRENCE; CLINICAL TRIAL; IMMUNOLOGY; MULTIMODALITY CANCER THERAPY; PHASE 1 CLINICAL TRIAL;

BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; GLIOBLASTOMA; HUMANS; IODINE RADIOISOTOPES; NEOPLASM RECURRENCE, LOCAL; RADIOIMMUNOTHERAPY; RADIOTHERAPY DOSAGE; TENASCIN;

EID: 0032588560     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Burger PC, Heinz ER, Shibata T, Kleihues P. Topographic anatomy and CT correlations in the untreated glioblastoma multiforme. J Neurosurg. 1988;68:698-704.
2. Hoshino T. A commentary on the biology and growth kinetics of low grade and high grade gliomas. J Neurosurg. 1984;61:895-900.
3. Wood JR, Green SB, Shapiro WR. The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group. J Clin Oncol. 1988;6:338-343.
4. Walker MD, Alexander E, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978;49:333-343.
5. Sheline GE . Radiotherapy for high grade gliomas. Int J Radiat Oncol Biol Phys. 1990;18:793-803.
6. Davies E, Clarke C, Hopkins A. Malignant cerebral glioma - I: Survival, disability, and morbidity after radiotherapy. Br Med J. 1996;313:1507-1512.
7. 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res. 1989;49:2807-2813.
8. Kemshead JT, Papanastassiou V, Coakham HB, et al. Monoclonal antibodies in the treatment of central nervous system malignancies. Eur J Cancer. 1992;28:511-513.
9. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res. 1988;48:7022-7032.
10. Riva P, Arista A, Tison V, et al. Intralesional radioimmunotherapy of malignant gliomas: an effective treatment in recurrent tumors. Cancer. 1994;73:1076-1082.
11. Hopkins K, Chandler C, Bullimore J, et al. A pilot study of the treatment of patients with recurrent malignant gliomas with intratumoral yttrium-90 radioimmunoconjugates. Radiother Oncol. 1995;34:121-131.
12. 131I monoclonal antibody: feasibility, pharmacokinetics and dosimetry. Br J Cancer. 1993;67:144-151.
13. 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results. Clin Cancer Res. 1996;2:963-972.
14. Bigner DD. Brown MT, Friedman AH, et al. Iodine-131-labeled anti-tenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J Clin Oncol. 1998;16:2202-2212.
15. Courtenay-Luck NS, Epenetos AA, Moore R. et al. Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms. Cancer Res. 1986;46:5489-6493.
16. Bourdon MA, Wikstrand CJ, Furthmayr H, et al. Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res. 1983;43:2796-2805.
17. Lindmo T, Boven E, Cuttitta F. et al. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984;72:77-89.
18. Leichner PK, Koral KF, Jaszczak RJ, et al. An overview of imaging techniques and physical aspects of treatment planning in radioimmunotherapy. Med Phys. 1993;20:569-577.
19. Israel O, Iosilevesky G. Front D, et al. SPECT quantification of I-131 concentration in phantoms and human tumors. J Nucl Med. 1990;31:1945-1949.
20. Leichner PK, Akabani G, Colcher D. et al. Patient-specific dosimetry of indium-II- and ytrium-90-labeled monoclonal antibody CC49. J Nucl Med. 1997;38:512-516.
21. Smith MF, Gilland DR, Coleman RE, Jaszczak RJ. Quantitative imaging of I-131 distributions in brain tumors with pinhole SPECT: a phantom study. J Nucl Med. 1998;39:856-864.
22. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theorelical considerations. J Nucl Med. 1993;34:689-694.
23. Siegel JA, Wessels BW, Watson EE, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunoconj Radiopharm. 1990;3:213-233.
24. Whitwell JR, Spiers FW. Calculated beta-ray dose factors for trabecular bone. Phys Med Biol. 1976;21:16-38.
25. Akabani G, Hawkins WG. Eckblade MB, et al. Patient specific dosimetry based on quantitative SPECT imaging and three-dimensional discrete Fourier transform convolution. J Nucl Med. 1997;38:308-314.
26. Halperin EC, Bentcl G, Heinz ER, Burger PC. Radiation therapy treatment planning in supratentorial glioblastoma multiforme: an analysis based on post mortem topographic anatomy with CT correlations. Int J Radiat Oncol Biol Phys. 1989;17:1347-1350.
27. Vick NA, Paleologos NA, External beam radiotherapy: hard facts and painful realities. J Neurooncol. 1995;24:93-95.
28. Leibel SA, Gutin PH, Wara WM, et al. Survival and quality of life after interstitial implantation of removable high-activity iodine-125 sources for the treatment of patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 1989;17:1129-1139.
29. Wen PY, Alexander E III, Black PM, et al. Long-term results of stereotactic brachytherapy used in the initial treatment of patients with glioblastomas. Cancer. 1994;73:3029-3036.
30. Behr TM, Sharkey RM, Juweid ME, et al. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG. J Nucl Med. 1997;38:858-870.
31. Tempero M, Leichner P, Dalrymple G, et al. High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial. J Clin Oncol. 1997;15:1518-1528.